25
Oct
In pancreatic cancer although early studies of maintenance sunitinib and fluorouracil have shown promising results1819 We conducted the POLO Pancreas Cancer. The study screened 3315 patients at 119 centers on 4 continents for germline BRCA mutations which were detected in 75 percent of patients.
Around 6-8 of pancreatic cancers harbour either BRCA or PALB2 mutations and the Polo investigators said 75 of the initially screened subjects were germline BRCA-positive.
Polo study pancreatic cancer. We conducted the POLO Pancreas Cancer Olaparib Ongoing trial to evaluate the efficacy of maintenance therapy with olaparib in patients with a germline BRCA mutation and metastatic pancreatic. A randomized phase III trial of olaparib maintenance monotherapy in patients pts with metastatic pancreatic cancer mPC who have a germline BRCA12 mutation gBRCAm. A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer mPC and a germline BRCA12 mutation gBRCAm who have not progressed following first-line chemotherapy.
Journal of Clinical Oncology. Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy POLO The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the US.
POLO trial for advanced pancreatic cancer. A new standard of care June 3 2019 Health Problems 0 Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer according to findings from the recently completed international phase-III POLO Pancreas cancer OLaparib Ongoing trial. POLO is a randomised double-blinded placebo-controlled multi-centre Phase III trial of Lynparza tablets 300mg twice daily as maintenance monotherapy versus placebo.
The trial randomised 154 patients with gBRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line platinum-based chemotherapy. The randomized double-blind placebo-controlled phase III POLO trial focused on a selected group of patients with metastatic pancreatic cancer who had inherited mutations in the BRCA 1 and 2. Pancreatic cancer begins when abnormal cells in the pancreas grow uncontrollably forming a tumor.
As the tumor continues to grow and spread it causes a myriad of symptoms such as pain in the abdomen radiating to the back weight loss yellowing of the skin and eyes nausea pancreatitis and diabetes. In pancreatic cancer although early studies of maintenance sunitinib and fluorouracil have shown promising results1819 We conducted the POLO Pancreas Cancer. Polo did not prospectively recruit subjects with the PALB2 genetic mutation.
Around 6-8 of pancreatic cancers harbour either BRCA or PALB2 mutations and the Polo investigators said 75 of the initially screened subjects were germline BRCA-positive. The rest of those that were excluded had already progressed during chemo. Doctors can treat pancreatic cancer that has spread with chemotherapy.
This wont cure it but can slow the growth of the cancer. Researchers think that olaparib may also slow down the growth of pancreatic cancer that has an inherited change in BRCA1 or BRCA2. Healthy cells can repair themselves if they get damaged.
The POLO study is a phase 3 randomized controlled trial of olaparib monotherapy in 154 patients with metastatic pancreatic adenocarcinoma with disease that had not progressed following. The randomized double-blind placebo-controlled phase III POLO trial focused on a selected group of patients with metastatic pancreatic cancer who had inherited mutations in the BRCA 1 and 2 genes. The study screened 3315 patients at 119 centers on 4 continents for germline BRCA mutations which were detected in 75 percent of patients.
A Phase III Randomised Double Blind Placebo Controlled Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy. Golans POLO trial not only represents the progression of cancer treatment towards precision medicine but offers hope and time to those with the most advanced form of pancreatic cancer underscoring the importance of participating in clinical trials. A near doubling of progression-free survival in the POLO study of AstraZenecaMerck Cos Lynparza could usher in a new era of targeted therapy for metastatic pancreatic patients with germline BRCA mutations and open up a third indication for the leading PARP inhibitor.
POLO is a randomised double-blinded placebo-controlled trial exploring the efficacy of Lynparza tablets as 1st-line maintenance monotherapy in patients with germline BRCA-mutated gBRCAm metastatic adenocarcinoma of the pancreas pancreatic cancer whose disease has not progressed on platinum-based chemotherapy. Golan is a lead researcher at the Pancreas Cancer Olaparib Ongoing POLO Clinical Trial at the Sheba Medical Center working specifically with patients with advanced stages of pancreatic cancer as well as a BRCA 1 or 2 germline mutation. NoCamels reported on her work this summer which offers a promising new drug regimen.
AstraZeneca AZN and Mercks Lynparza significantly delays disease progression in a late-stage study POLO evaluating it as first-line maintenance treatment in pancreatic cancer.